Mandolgin (Tramadol Hydrochloride)

Tramadol acts centrally by binding to μ‑opioid receptors, producing opioid‑type analgesia, while also blocking the reuptake of norepinephrine and serotonin. This combined effect enhances the body’s natural pain‑inhibiting pathways, reducing the perception of pain.

The appropriate dose of Mandolgin is determined by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions exactly.

Safety of tramadol during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mandolgin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Mandolgin (tramadol) is a centrally acting opioid with a dual mechanism that also influences serotonin and norepinephrine pathways, offering analgesia with a lower risk of respiratory depression compared with stronger opioids such as morphine. However, it carries its own risk profile, including potential for seizures and serotonin syndrome, especially when combined with certain drugs.

Mandolgin should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and out of reach of children to maintain its stability and potency.

Mandolgin is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The medication should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include respiratory depression, seizures, serotonin syndrome, severe allergic reactions, and the potential for dependence or abuse. Patients should seek immediate medical attention if they experience difficulty breathing, uncontrolled shaking, high fever, rash, or any signs of overdose.

Mandolgin should be avoided in individuals with known hypersensitivity to tramadol, those currently taking monoamine oxidase inhibitors, patients with uncontrolled epilepsy, severe respiratory depression, or in whom opioid analgesics are contraindicated. A healthcare professional must evaluate suitability before prescribing.